Australia Markets closed

The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough

Tom Richardson
Healthy Heart

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions. 

CelGro® is reportedly used by surgeons to help patients regain muscle function via nerve regeneration treatment.

According to the company 12 patients undertook the trial with 86% of them subsequently reducing or ceasing to need prescription medication for chronic nerve pain 12 months after their treatment with CelGro®.

While 96% of “nerve repairs restored voluntary movement to previously paralysed muscle” in allowing previously quadriplegic patients to now undertake some common everyday tasks. 

Orthocell estimates CelGro®’s addressable market to be worth around US$1.1 billion annually, with 700,000 procedures completed each year that could be improved by CelGro®.

All this sounds exciting and at 50 cents per share Orthocell now has a market value around $74 million. For the 12 months to June 30 2019 it posted a net loss of $5.8 million on sales of $945,657. 

I would not suggest buying Orthocell shares myself, but the share price action shows it’s exciting risk on investors. 

Other speculative biotech picks exciting investors include Althea Group Holdings Ltd (ASX: ATH) Paradigm Biopharmaceuticals Ltd (ASX: PAR) and Opthea Ltd (ASX: OPT).

The post The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough appeared first on Motley Fool Australia.

NEW! Top 3 Dividend Bets for 2019

With interest rates likely to stay at rock bottom for months (or YEARS) to come, income-minded investors have nowhere to turn... except dividend shares. That’s why The Motley Fool’s top analysts have just prepared a brand-new report, laying out their top 3 dividend bets for 2019.

Hint: These are 3 shares you’ve probably never come across before.

They’re not the banks. Not Woolies or Wesfarmers or any of the “usual suspects.”

We think these 3 shares offer solid growth prospects over the next 12 months. Each of these three companies boasts fully franked yields and could be a great fit for your diversified portfolio. You’ll discover all three names and codes in "The Motley Fool’s Top 3 Dividend Shares for 2019."

Even better, your copy is free when you click the link below. Fair warning: This report is brand new and may not be available forever. Click the link below to be among the first investors to get access to this timely, important new research!

The names of these top 3 dividend bets are all included. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies move – we may be forced to remove this report.

Click here to claim your free copy right now!

More reading

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019